Structure Therapeutics Inc.
structuretx.comWhat Do They Do?
Develops oral small-molecule medicines for chronic metabolic diseases, including obesity and related conditions, using a drug-discovery platform focused on GPCRs.
10-K for FY2025, filed Feb 26, 2026We are a clinical stage global biopharmaceutical company developing novel oral small molecule therapeutics to treat a wide range of chronic…View ↗
Our most advanced product candidate to date is aleniglipron, also known as GSBR-1290, an oral small molecule selective…View ↗
We pursue opportunities to target GPCRs in human diseases on the basis of validated biology, safety, development feasibility and market…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Feb 26, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$106.2MView ↗
- ▲ +72% (Loss)
- vs −$61.7M in Q2 FY2025
-
Sep 8, 2026
Reports clinical results for amylin and GLP-1 drug candidates
ACCG-2671 reported single-dose findings, and aleniglipron reported 72-week extension results.
Sources
8-K, filed Sep 8, 2026
ACCG-2671 (Oral Small Molecule DACRA): Phase 1 SAD Topline Clinical Trial ResultsView ↗
-
May 7, 2026
Expanded share sales agreement
The prospectus supplement increased the available offering amount.
Sources
8-K, filed May 7, 2026
On May 7, 2026, Structure Therapeutics Inc. (the “Company”) amended and restated that certain Sales Agreement dated August 6, 2025 (the…View ↗
Who Do They Compete With?
Competes with Pfizer, Eli Lilly, Qilu Regor Therapeutics, AstraZeneca/Eccogene, Terns Pharmaceuticals, Jiangsu Hengrui Medicine, Huadong, Sciwind Biosciences, Ascletis, Gilead, Kallyope, MindRank, vTv Therapeutics, Carmot Therapeutics, Roche Group, Kailera Therapeutics, Merck, Hansoh Pharma, Novo Nordisk, and Sanofi
10-K for FY2025, filed Feb 26, 2026Despite significant biopharmaceutical industry investment, no oral small molecule therapy targeting GLP-1R has been approved for the…View ↗
Loading...
